Doxifluridine

Trade name: furtulon

Small moleculeexperimental

Doxifluridine (5'-deoxy-5-fluorouridine) is a second generation nucleoside analog prodrug developed by Roche and used as a cytostatic agent in chemotherapy in several Asian countries including China and South Korea. Doxifluridine is not FDA-approved for use in the USA. It is currently being evaluated in several clinical trials as a stand-alone or combination therapy treatment. — Wikipedia

Clinical trial activity

3 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
1

Earliest trial started Oct 1, 2001 (NCT00296322)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
Mol. weight
246.19 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • 5'-deoxy-5-fluorouridine
  • 5'-deoxy-5-fluorouridine
  • 5'-deoxy-5-fluorouridine
  • 5'-deoxy-5'-fluorouridine
  • 5-dfur
  • 5-dfur
  • 5-dfur
  • 5-dfur
  • 5'-dfur
  • 5'-fluoro-5'-deoxyuridine
  • doxfluridine
  • doxifluridine
  • doxifluridine
  • doxifluridine
  • doxifluridine
  • doxifluridine
  • doxifluridine
  • doxifluridine
  • doxyfluridine
  • flutron
  • furtulon
  • furtulon
  • ro 21-9738
  • uridine-5'-deoxy-5-fluoro-

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01401075Phase 4Mar 1, 2006Abnoba, University of Ulsan
NCT00296335Phase 3Feb 1, 2002Hallym University, University of Ulsan
NCT00296322Phase 3Oct 1, 2001Hallym University, University of Ulsan
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of UlsanAcademic/Hospital3222001
Hallym UniversityAcademic/Hospital2012001
AbnobaFor profit1112006
3 organizations
Page 1 / 1